Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Lenvatinib, and HAIC for Borderline Resectable HCC
NCT06904014Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, lenvatinib in hepatocellular carcinoma (HCC). Started Oct 2023; status: recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06904014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904014.